- GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater
- GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress
- GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025
- GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations
- GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum
- GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates
- GeoVax to Present Clinical Data at Upcoming April Industry Events
- GeoVax to Present at the Emerging Growth Conference on April 16, 2025
- GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent
- GeoVax Reports 2024 Year-End Financial Results and Provides Business Update
- GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- GeoVax to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
- GeoVax Establishing Strategic Presence in Europe with Initial Footprint in the UK
- GeoVax to Present at the 37th Annual Roth Conference
- Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event “MPOX 2025: Navigating the Global Public Health Emergency” Featuring GeoVax CEO On March 6, 2025
- GeoVax Highlights the Critical Role of MVA-Based Vaccines in U.S. Biodefense Strategy
- GeoVax Response to WHO’s Third Declaration of Mpox as a Public Health Emergency of International Concern
- GeoVax Highlights the Role of MVA-Based Vaccines in Advancing Public Health Preparedness
- Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification
- GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health
- GeoVax to Present at the Emerging Growth Conference on February 19, 2025
- GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award
- GeoVax Anticipates Significant 2025 Progress with Catalyst-Rich Milestones Across Key Programs
- GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference
- GeoVax Announces Strategic Integration of AI in Support of President Trump’s Stargate Initiative
- Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability
- GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide
- GeoVax Announces Major Gedeptin® Milestone with Plans of Phase 2 Trial
- GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024
- GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025
- GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025
- GeoVax Receives Notice of Allowance For Cancer Vaccine Patent
- GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference
- GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
- GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
- GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024
- GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
- GeoVax to Participate in Upcoming Investor Conferences in September
- GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market
- Registration Is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO
- GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market
- GeoVax to Present at the Emerging Growth Conference on August 21, 2024
- GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
- GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
- GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review
- GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024
- GeoVax to Present at the Emerging Growth Conference on July 18, 2024
- GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market
- GeoVax Provides First Half 2024 Business Update
- GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA
